Laval, Québec, CANADA – March 6, 2012 – Acasti Pharma Inc. (“Acasti”) (TSX-V.APO), a Neptune Technologies & Bioressources Inc. (“Neptune”) subsidiary, announces it will be presenting at the 24th Annual Roth Conference and that it has granted incentive stock options.

Acasti at The 24th Annual Roth Conference:
Monday, March 12, 2012
4:30 PM, Pacific Time
Ritz Carlton Hotel, Dana Point, California
Speaker : Harlan Waksal, M.D., Executive Vice-President, Business & Scientific Affairs

The 24th annual Roth  Conference is taking place in California from March 11 to 14, 2012.  Over 400 companies selected by Roth Capital Partners will be represented at the conference and the organizers expect over 1000 buy-side investors. This event is designed to provide investors with a unique opportunity to gain insight into small and mid-cap growth companies across a variety of sectors.

A webcast of the presentation will be available on the Acasti website at www.acastipharma.com shortly after the presentation.

Incentive Stock Options
As of March 5th, 2012, the Board of Directors, as part of its annual review of direct and indirect remunerations, decided to grant a total of 2,105,000 incentive stock options of Acasti to employees, executives officers and directors.  Acasti incentive stock options have an exercice price of $2 and a 5 year maturity.  Insiders have been granted a total of 1,450,000 Acasti incentive stock options.

The options were granted subject to provisions of the Company's stock option plan which was approved by shareholders in June 2011, and subject to the TSX policies and the applicable securities laws.